Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

Kulkarni, 2021 CTRI/2020/08/027170

Covishield (Oxford/AZ formulation) (n=1200) vs. placebo (n=300)

randomized controlled trial   risk of bias NA

Studied treatment

SII-ChAdOx1 nCoV-19
Two doses of vaccine at a dosing interval of 4 ( 2) weeks

Control treatment

placebo

Patients

COVID-19 prophylaxis (excluding children)

Method

double-blind

14 hospitals across India

Remark